NIHR Global Health Research Group on Vaccines to Control Respiratory Pathogens and AMR across Africa, Institute of Infection, Immunity and Transplantation, University College London, London, UK
Auto-generated profile, based on publicly available information
Rory Cave
NIHR Global Health Research Group on Vaccines to Control Respiratory Pathogens and AMR across Africa, Institute of Infection, Immunity and Transplantation, University College London, London, UK
Enzymatic inactivation of Rho-family GTPases by the glucosyltransferase domain of Clostridioides difficile Toxin B (TcdB) gives rise to various pathogenic effects in cells that are classically thought to be responsible for the disease symptoms associated with C. difficile infection (CDI). Recent in vitro studies have shown that TcdB can, under certain circumstances, induce cellular toxicities that are independent of glucosyltransferase (GT) activity, calling into question the precise role of GT activity. Here, to establish the importance of GT activity in CDI disease pathogenesis, we generated the first described mutant strain of C. difficile producing glucosyltransferase-defective (GT-defective) toxin. Using allelic exchange (AE) technology, we first deleted tcdA in C. difficile 630Δerm and subsequently introduced a deactivating D270N substitution in the GT domain of TcdB. To examine the role of GT activity in vivo, we tested each strain in two different animal models of CDI pathogenesis. In the non-lethal murine model of infection, the GT-defective mutant induced minimal pathology in host tissues as compared to the profound caecal inflammation seen in the wild-type and 630ΔermΔtcdA (ΔtcdA) strains. In the more sensitive hamster model of CDI, whereas hamsters in the wild-type or ΔtcdA groups succumbed to fulminant infection within 4 days, all hamsters infected with the GT-defective mutant survived the 10-day infection period without primary symptoms of CDI or evidence of caecal inflammation. These data demonstrate that GT activity is indispensable for disease pathogenesis and reaffirm its central role in disease and its importance as a therapeutic target for small-molecule inhibition. Novel non-antibiotic therapies are required for the treatment of Clostridioides difficile infection (CDI). An emerging class of promising therapeutics for CDI are antivirulence agents that block the actions of C. difficile Toxin B (TcdB), the primary determinant of virulence. In order to develop such treatments, molecular targets and mechanisms must be identified and validated. Historically the glucosyltransferase domain (GTD) represented an ideal target owing to its perceived importance for disease pathogenesis. However, studies capitalizing on recent advances in recombinant TcdB production have unveiled GTD-independent mechanisms of toxicity when applied at high concentrations in vitro, thus questioning the role of the GTD. Here we generate the first-reported mutant strain of C. difficile expressing glucosyltransferase-defective TcdB. Application thereof demonstrates that the GTD is essential for disease in mice and hamsters, thus reoffering the GTD as an ideal candidate for small-molecule inhibitor (SMI) development.
Since the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Malawi in 2011, there has been persistent carriage of vaccine serotype (VT) Streptococcus pneumoniae, despite high vaccine coverage. To determine if there has been a genetic change within the VT capsule polysaccharide (cps) loci since the vaccine’s introduction, we compared 1022 whole-genome-sequenced VT isolates from 1998 to 2019. We identified the clonal expansion of a multidrug-resistant, penicillin non-susceptible serotype 23F GPSC14-ST2059 lineage, a serotype 14 GPSC9-ST782 lineage and a novel serotype 14 sequence type GPSC9-ST18728 lineage. Serotype 23F GPSC14-ST2059 had an I253T mutation within the capsule oligosaccharide repeat unit polymerase Wzy protein, which is predicted in silico to alter the protein pocket cavity. Moreover, serotype 23F GPSC14-ST2059 had SNPs in the DNA binding sites for the cps transcriptional repressors CspR and SpxR. Serotype 14 GPSC9-ST782 harbours a non-truncated version of the large repetitive protein (Lrp), containing a Cna protein B-type domain which is also present in proteins associated with infection and colonisation. These emergent lineages also harboured genes associated with antibiotic resistance, and the promotion of colonisation and infection which were absent in other lineages of the same serotype. Together these data suggest that in addition to serotype replacement, modifications of the capsule locus associated with changes in virulence factor expression and antibiotic resistance may promote vaccine escape. In summary, the study highlights that the persistence of vaccine serotype carriage despite high vaccine coverage in Malawi may be partly caused by expansion of VT lineages post-PCV13 rollout.
Controlling the carriage and transmission of Streptococcus pneumoniae in children from high-burden settings is critical for disease prevention. To investigate the rate and drivers of transmission following pneumococcal conjugate vaccine (PCV) introduction, we estimated evolutionary divergence times using whole-genome sequences of S. pneumoniae from 1,617 children in Blantyre, Malawi (2015–2019). The cohort included PCV13-vaccinated children aged 2–7 years and unvaccinated children aged 5–10 years who were vaccine ineligible at the time of rollout into routine use. Using generalized additive mixed models and relative risk frameworks that incorporated household geospatial distances, we found that pneumococcal lineages spread widely across Blantyre within ~4 years, with transmission most likely between neighbouring households. Logistic regression and random forest models identified higher transmission risk among preschool-aged children in densely populated, higher socioeconomic areas. Recent transmission events were primarily associated with expanding, non-vaccine serotype lineages that were non-susceptible to penicillin. These findings highlight the potential for extended valency PCVs to reduce the spread of disease-causing and antimicrobial-resistant pneumococcal lineages among preschool-aged children, particularly in high-density areas – thereby strengthening herd protection for vulnerable groups such as young infants and individuals living with HIV.
Controlling the carriage and transmission of Streptococcus pneumoniae in children from high- disease burden countries is crucial for disease prevention. To assess the rate of spread, and the factors associated with the high frequency of transmission despite pneumococcal conjugate vaccine (PCV) introduction, we measured evolution divergence time using the whole genome sequences of S. pneumoniae collected from 1,617 child participants from Blantyre, Malawi between 2015 and 2019. These children included both PCV13 vaccinated children aged 2 to 7 years and PCV13 unvaccinated children aged 5 to 10 years who were age ineligible when PCV was introduced. Using a generalized additive mixed model (GAMM) and relative risk (RR) frameworks, while accounting for household geospatial distances, we found that the spread of lineages became widespread across the population of Blantyre over approximately four years, with transmission being more likely between neighbouring households. Logistic regression and random forest models predicted a higher incidence of events among preschool children in densely populated, higher socioeconomic areas. Additionally, recent transmission was linked to recently expanding, non-vaccine serotype lineages that are penicillin non-susceptible. Our findings suggest that enhancing vaccine-mediated immunity among preschool-aged children in high density settings could reduce transmission of disease-causing and antimicrobial-resistant pneumococcal lineages, therefore strengthening herd protection for vulnerable individuals (e.g. very young children and people living with HIV).
Background Urinary tract infections (UTIs) are a leading cause of hospitalization in people living with dementia, making accurate detection and prompt treatment critical in this vulnerable population. Methods This retrospective, longitudinal cohort study evaluated the diagnostic accuracy of self-reported symptoms and urine dipstick test results for identifying UTIs in people with dementia. Participants included 78 community-dwelling individuals over the age of 50 with a confirmed dementia diagnosis. These participants were recruited from cohorts established by the Surrey and Borders Partnership NHS Foundation Trust and the Hammersmith & Fulham Partnership Primary Care Network between late 2019 and 2023. Results The frequency of UTIs in people living with dementia (PLWD) is highly variable, some individuals having nearly chronic infections and others not acquiring a single UTI during their enrolment in the study. The taxonomy of the microbes associated with the urinary tract infections in this cohort were consistent with those that have been observed in other demographics. When we modelled the relationship between self-reported symptoms, dipstick results, and the presence of UTIs we found that there was no significant relationship between UTI and symptoms. However, there was a highly significant correlation between dipstick test results positive for leucocytes and nitrites with the presence of a UTI. Conclusions Urine dipstick tests for nitrites and leucocytes should be incorporated into diagnostic protocols and should also be considered for ongoing surveillance of UTIs in people living with dementia. Study Registration Numbers Research Ethics Committee (REC) reference: 19/LO/0102 Integrated Research Application System (IRAS) project ID: 257561